In addition to gene therapies designed to boost SMN protein production, other preclinical animal studies are being rigorously pursued aimed at uncovering novel indirect or non-SMN disease modifiers as targets for AAV-based gene therapies to treat SMA or to facilitate current SMA treatments. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.